A study of intravitreal injection of ganciclovir for herpetic intraocular infectious diseases

A study of intravitreal injection of ganciclovir for herpetic intraocular infectious diseases - A study of intravitreal injection of ganciclovir for herpetic intraocular infectious diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029657

Enrollment

Registered

2017-10-23

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraocular infectious diseases due to human herpes viruses

Interventions

Perform intravitreal ganciclovir (1000 ug/100 ul) injection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The eyes in which herpes simplex viruses, varicella-zoster virus, or cytomegalovirus was detected by PCR using intraocular fluids, or for the eyes in which human herpes virus infection is strongly suspected and there is a high possibility that the eye will go blind due to retinal necrosis or secondary glaucoma.

Exclusion criteria

Exclusion criteria: History of serious adverse reactions by methotrexate

Design outcomes

Primary

Measure	Time frame
Remission of the intraocular inflammation, visual acuity, and recurrence rate in two years.	—

Secondary

Measure	Time frame
Rate of adverse events, and relapse rate (central nerve system and other lesion)	—

Countries

Japan

Contacts

Public ContactHiroshi Takase

Tokyo Medical and Dental University Department of Ophthalmology & Visual Science

h.takase.oph@tmd.ac.jp+81-3-5803-5302

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026